• Alembic Pharma

    Alembic (APL) is planning to launch 20-25 products in India. Company expects to launch derma products in FY20E and injectable products from FY21E in the US market. We expect CAGR of 12%/11% in revenue/PAT over FY19E-21E. Margins would be flat over FY19E and...

    Buy Reco. Price: 559.00

  • Aurobindo Pharma

    Aurobindo has acquired the generic drug and branded dermatology portfolio from Sandoz at 6.2x EV/EBITDA. The deal is value accretive and has added 300 ANDAs in Aurobindo’s portfolio as well as three manufacturing facilities. We are positive on Aurobin...

    Buy Reco. Price: 761.00

  • Lupin

    Lupin is facing high competition and pricing pressure in key products such as gGlumetza and gFortamet. While successful audits by Health Canada (Pithampur-II) and UK-MHRA (Goa) have eased some regulatory pressure, USFDA clearance to the Goa/Pithampur-II pla...

    Sell Reco. Price: 830.00